You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Secondary AML patient stories

Explore stories from secondary acute myeloid leukemia (sAML) patients, or share your experience from diagnosis through treatment with VYXEOS (vix-e-ose). Individual results may vary.

Tim’s story

Tim and his family discuss his diagnosis of sAML with myelodysplasia-related changes (AML-MRC) and subsequent treatment with VYXEOS, followed by transplant.

Speech Bubble icon

My approach to how I was going to battle the illness was to fight it—to work really hard and do everything I could to put myself in the best position to be successful.

-TIM

John’s story

John shares his journey, from being diagnosed with AML-MRC to his personal experience with VYXEOS.

Speech Bubble icon

My advice for somebody going through this is have the support, have a positive attitude, keep in shape, the best shape you can be.

-JOHN

Do you want to share your VYXEOS story with us?

Please enter your first name and phone number below and a member of our team will reach out to you regarding your treatment story. Please note your time zone and what time is best to reach you.

    * Required field

    Jazz Pharmaceuticals respects your interest in keeping your personal information private. The personal information you provide will be used by Jazz Pharmaceuticals and the third parties working with Jazz Pharmaceuticals to respond to your request. We will not sell or rent your personal information to any third party. For more information about how Jazz Pharmaceuticals uses and protects your personal information, please click here to view our Privacy Statement. If in the future you no longer want to receive communications from Jazz Pharmaceuticals, please click here or contact us at 1-800-833-3533.

    WHAT IS VYXEOS?

    VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

    IMPORTANT SAFETY INFORMATION

    Important Safety Information

    VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.